Afatinib with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutation:phaseI study
Phase 1
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000015944
- Lead Sponsor
- Okayama Lung Cancer Study Group (OLCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) EGFR mutation (exon20) 2) Symptomatic brain metastases 3) Leptomeningeal carcinomatosis 4) Active double cancer 5) Hemoptysis or hemosputum 6) Hemophilic arthritis 7) Antiplatelet drug or anticoagulant 8) Uncontrolled high tension 9) Invasion to major arteries or vessels 10) Cavity of lung tumor 11) Therapy needed effusion (pleural or pericardial or ascites) 12) SVC syndrome 13) Interstitial pneumonitis or pneumonia 14) Gastrointestinal disturbance 15) Severe allergic history 16) Pregnancy 17) Inadequate patients whom physitians considered
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence rates of dose limiting toxicity (DLT) in each therapy dose
- Secondary Outcome Measures
Name Time Method